Skip to main content

View Resource

Published

Three-year follow-up of the COVAXID trial: real-world assessment of SARS-CoV-2 mRNA vaccine immunogenicity in immunocompromised individuals highlights increasing roles of hybrid and passive immunity.
Chen P. eBioMedicine 2026;:https://doi.org/10.1016/j.ebiom.2026.106279.
[Immunocompromised individuals were identified early in the pandemic as being at increased risk of severe COVID-19 and demonstrated variable immune responses to SARS-CoV-2 vaccination. The findings support continued, tailored vaccination strategies for elderly and immunocompromised individuals. Integrating immune monitoring with infection history and adjunctive therapies may help refine booster policies, optimise protection, and strengthen future vaccination programmes for high-risk populations.]
Freely available online
Age Groups
Adults
Older People
Conditions and Lifestyle Factors
Coronavirus Infections
Settings
Population Health
Staff Groups
Immunisation
Public Health Doctor
Public Health Specialist